AZD4360
/ AstraZeneca
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
August 01, 2026
Study for AZD4360 in Participants With Advanced Solid Tumours
(clinicaltrials.gov)
- P1/2 | N=31 | Active, not recruiting | Sponsor: AstraZeneca | N=117 ➔ 31 | Recruiting ➔ Active, not recruiting
Enrollment change • Enrollment closed • Biliary Cancer • Biliary Tract Cancer • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • CLDN18
April 28, 2026
AZD4360: Data from P1/2 CONCLUDE trial (NCT06921928) for solid tumors in 2027
(AstraZeneca)
- Q1 2026 Results
P1/2 data • Oncology • Solid Tumor
February 18, 2026
D8930C00001: A trial to learn how safe AZD4360 is, how well it works, and how it moves throughout the body over time in adults with advanced solid tumors
(clinicaltrialsregister.eu)
- P1/2 | N=17 | Recruiting | Sponsor: AstraZeneca AB
New P1/2 trial • Biliary Cancer • Biliary Tract Cancer • Esophageal Cancer • Gastric Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • CLDN18
July 29, 2025
AZD4360: Data from P1/2 trial (NCT06921928) for solid tumors post 2026
(AstraZeneca)
- H1 & Q2 2025 Results
P1/2 data • Oncology • Solid Tumor
July 02, 2025
Study for AZD4360 in Participants With Advanced Solid Tumours
(clinicaltrials.gov)
- P1/2 | N=117 | Recruiting | Sponsor: AstraZeneca | Trial primary completion date: Jul 2027 ➔ Mar 2027
Trial primary completion date • Biliary Cancer • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Oncology • Pancreatic Cancer • Solid Tumor
May 21, 2025
Study for AZD4360 in Participants With Advanced Solid Tumours
(clinicaltrials.gov)
- P1/2 | N=117 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting
Enrollment open • Biliary Cancer • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Oncology • Pancreatic Cancer • Solid Tumor
April 11, 2025
Study for AZD4360 in Participants With Advanced Solid Tumours
(clinicaltrials.gov)
- P1/2 | N=117 | Not yet recruiting | Sponsor: AstraZeneca
New P1/2 trial • Biliary Cancer • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor
1 to 7
Of
7
Go to page
1